The potential of selected prostanoid receptors as targets in a new therapeutic strategy for allergy and immune diseases

Current Drug Safety

Volumn 2, Issue 3, 2007, Pages 186-192

  Kabashima, Kenji ^a   Tokura, Yoshiki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Asthma; Atopic dermatitis; Contact dermatitis; NSAID; Prostaglandin; Prostanoid

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 4; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN G2; PROSTAGLANDIN H2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROSTANOID RECEPTOR; STEROID; THROMBOXANE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ALLERGY; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BRONCHOSPASM; CELL MIGRATION; CONTACT DERMATITIS; DENDRITIC CELL; DRUG SELECTIVITY; DRUG TARGETING; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOLOGY; LYMPH NODE; MEMORY T LYMPHOCYTE; MOLECULAR BIOLOGY; NONHUMAN; OBESITY; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; RHINITIS; SKIN DISEASE; TH2 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG DELIVERY SYSTEMS; HUMANS; HYPERSENSITIVITY; IMMUNE SYSTEM DISEASES; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN; SKIN;

EID: 35348821816     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607781668864     Document Type: Review

References (57)

1. Spergel JM. Atopic march: link to upper airways. Curr Opin Allergy Cho Immunol. 2005; 5: 17-21.
2. Marenholz I, Nickel R, Ruschendorf F, et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol 2006; 118: 866-871.
3. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphy-laxis, and hypersensitivity reactions to foods, drugs, and insects. J Allergy Clin Inummol 2007; [Epub ahead of print].
4. Abramovits W, Perlmutter A. Steroids versus other immune modulators in the management of allergic dermatoses. Curr Opin Allergy Clin Immunol 2006; 6: 345-354.
5. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
6. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001; 108: 25-30.
7. Scholz K, Furstenberger G, Muller-Decker K, Marks F. Differential expression of prostaglandin-H synthase isoenzymes in normal and activated keratinocytes in vivo and in vitro. Biochem J 1995; 309 (Pt 1): 263-269.
8. Leong J, Hughes-Fulford M, Rakhlin N, et al. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res 1996; 224: 79-87.
9. Torii E, Segi E, Sugimoto Y, et al. Expression of prostaglandin E(2) receptor subtypes in mouse hair follicles. Biochem Biophys Res Commun 2002; 290: 696-700.
10. Hammarstrom S, Lindgren JA, Marcelo C, et al. Arachidonic acid transformations in normal and psoriatic skin. J Invest Dermatol 1979; 73: 180-183.
11. Ujihara M, Horiguchi Y, Ikai K, Urade Y. Characterization and distribution of prostaglandin D synthetase in rat skin. J Invest Dermatol 1988; 90: 448-451.
12. Ruzicka T, Aubock J. Arachidonic acid metabolism in guinea pig Langerhans cells: studies on cyclooxygenase and lipoxygenase pathways. J Immunol 1987; 138: 539-543.
13. Kabashima K, Murata T, Tanaka H, et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol 2003; 4: 694-701.
14. Konger RL, Malaviya R, Pentland AP. Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes. Biochim Biophys Acta 1998; 1401: 221-234.
15. Tober KL, Wilgus TA, Kusewitt DF, et al. Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol 2006; 126: 205-211.
16. Angeli V, Faveeuw C, Roye O, et al. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J Exp Med 2001; 193: 1135-1147.
17. Kabashima K, Sakata D, Nagamachi M, et al. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003; 9: 744-749.
18. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294: 870-875.
19. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15-23.
20. Takahashi Y, Tokuoka S, Masuda T, et al. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br J Pharmacol 2002; 137: 315-322.
21. Nataraj C, Thomas DW, Tilley SL, et al. Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest 2001; 108: 1229-1235.
22. Fedyk ER, Phipps RP. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci U S A 1996; 93: 10978-10983.
23. Nguyen M, Solle M, Audoly LP, et al. Receptors and signaling mechanisms required for prostaglandin E2-mediated regulation of mast cell degranulation and IL-6 production. J Immunol 2002; 169: 4586-4593.
24. Kunikata T, Yamane H, Segi E, et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol 2005; 6: 524-531.
25. Mita H, Hasegawa M, Higashi N, Akiyama K. Characterization of PGE2 receptor subtypes in human eosinophils. J Allergy Clin Immunol 2002; 110: 457-459.
26. Peacock CD, Misso NL, Watkins,DN, Thompson PJ. PGE 2 and dibuti cyclic adenosine monophosphate prolong eosinophil survival in vitro. J Allergy Clin Inummol. 1999; 104: 153-162.
27. Yamane H, Sugimoto Y, Tanaka S, Ichikawa A. Prostiglandin E(2) receptors, EP2 and EP4, differentially modulate TNF-alpha and IL6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem Biophys Res Commun 2000; 278: 224-228.
28. Kabashima K, Miyachi, Y. Pmstanoids in the cutaneous immune response. J Dermatol Sci 2004; 34: 177-184.
29. Youn CS, Cho KH. Eosinophilic pustular folliculitis treated with naproxen. Br J Dermatol 2001; 145: 514-515.
30. Wong RC, Kang S, Heezen JL, Voorhees JJ, Ellis CN. Oral ibuprofen and tetracycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984; 11: 1076-1081.
31. Szczeklik A, Stevenson, DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol, 1999; 104: 5-13.
32. Becker D, Knop J. Mechanism in allergic contact dermatitis. Exp Dermatol 1993; 2: 63-69.
33. Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998; 19: 37-44.
34. Zhou W, Hashimoto K, Goleniewska K, et al. Prostaglandin i2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 2007; 178: 702-710.
35. Robbiani DF, Finch RA, Jager D, et al. The leukotrieve C(4) transporter MRPI regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000; 103: 757-768.
36. Rocca B, Spain LM, Pure E, et al. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 1999; 103: 1469-1477.
37. Goodwin JS, Webb DR. Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol 1980; 15: 106-122.
38. Kunkel SL, Chensue SW, Phan SH. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol 1986; 136: 186-192.
39. Homey B, Alenius H, Muller A, et al. CCL27-CCRIO interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-165.
40. Murakawa M, Yamaoka K, Tanaka Y, Fukuda Y. Involvement of tumor necrosis factor (TNF)-alpha in phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA)-induced skin edema in mice. Biochern Pharmacol 2006; 71: 1331-1336.
41. Flower RJ, Harvey EA, Kingston WP. Inflammatory effects of prostaglandin D2 in rat and human skin. Br J Pharmacol 1976; 56: 229-233.
42. Crunkhorn P, Willis AL. Cutaneous reactions to intradermal prostaglandins, Br J Pharmacol 1971; 41: 49-56.
43. Basran GS, Morley J, Paul W, Tumer-Warwick M. Evidence in man of synergistic interaction between putative mediators of acute inflammation and asthma. Lancet 1982; 1: 935-937.
44. Kabashima K, Nagamachi M, Honda T, et al. Prostaglandin E(2) is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors. Lab Invest 2007; 87: 49-55.
45. Kawashima M, Harada S. Effect of standard medication on quality of life of patients with atopic dermatitis. J Dermatol 2007; 34: 9-16.
46. Kawashima M, Tango T, Noguchi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, plazebo-controlled, parallel-group study. Br 3 Dermatol 2003; 148: 1212-1221.
47. Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2, and leukotriene B4 are present in biologically active concentrations. J Allergy Clin Immunol 1989; 83: 450-455.
48. Archer CB, Page CP, Juhlin L, Morley J, MacDonald DM. Delayed-onset synergism between leukotriene B4 and prostaglandin E2 in human skin. Prostaglandins 1987; 33: 799-805.
49. Archer CB, Frohlich W, Page CW, et al. Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man. Prostaglandins 1984; 27: 495-501.
50. Lee CH, Chuang HY, Shih CC, et al. Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. Br J Dermatol 2006; 154: 1100-1107.
51. Matsuoka T, Hirata K Tanaka H, et al. Prostaglandin D2 as a mediator of allergic astlima. Science 2000; 287: 2013-2017.
52. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193: 255-261.
53. Yoshimura-Uchiyama C, Iikura M, Yamaguchi M, et al. Differential modulation of human basophil functions through prostaglandin D2. receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clin Exp Allergy 2004; 34: l283-1290.
54. Takeshita K, Yamasaki T, Nagao K, et al. CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. Int Iummnol 2004; 16: 947-959.
55. Iwasaki M, Nagata K, Takano S, et al. Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis, J Invest Dermatol 2002; 119: 609-616.
56. Neisius U, Olsson R, Rukwied R, Lischetzki G, Schmalz M. Prostaglandin E2 induces vasodilation and pruritus, but no proutein ex-travasation in atopic dermatitis and controls. J Am Acad Dermatol 2002; 47: 28-32.
57. Arai I, Takano N, Hashimoto Y, et al, Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2004; 505: 229-235.